VICP Registry Case Source Bundle
Canonical URL: https://vicp-registry.org/case/USCOURTS-cofc-1_24-vv-01697
Package ID: USCOURTS-cofc-1_24-vv-01697
Petitioner: Charles Jones
Filed: 2024-10-18
Decided: 2026-03-10
Vaccine: influenza
Vaccination date: 2023-10-01
Condition: Guillain-Barre Syndrome (GBS)
Outcome: compensated
Award amount USD: 178000

AI-assisted case summary:
On October 18, 2024, Charles Jones filed a petition alleging that an influenza vaccination administered on October 1, 2023 caused Guillain-Barre Syndrome, a Vaccine Injury Table injury. Respondent conceded entitlement in a Rule 4(c) report, and Chief Special Master Brian H. Corcoran found Mr. Jones entitled to compensation on July 11, 2025.

The parties could not resolve damages and briefed pain and suffering. Mr. Jones sought $185,000.00, describing a severe and debilitating GBS course. Respondent proposed $148,000.00, characterizing the illness as moderate while later acknowledging that Mr. Jones had experienced upper and lower extremity weakness, deficits, and neurologic symptoms for at least two years. The Special Master compared the case to other GBS pain-and-suffering awards involving moderate symptoms, hospital and inpatient rehabilitation stays, and significant outpatient therapy.

On March 10, 2026, Chief Special Master Corcoran awarded $178,000.00 for past pain and suffering. No separate unreimbursed expenses, future expenses, or lost wages were awarded in the decision.

Theory of causation field:
Influenza vaccine on October 1, 2023, causing Table GBS; COMPENSATED. Respondent conceded entitlement. Damages contested: petitioner sought $185,000; respondent proposed $148,000; decision credited moderate but significant GBS with upper/lower extremity weakness and neurologic symptoms persisting at least two years. Award $178,000 past pain/suffering only. Chief SM Brian H. Corcoran; petition filed October 18, 2024; entitlement July 11, 2025; damages March 10, 2026.

Public staged source text:

================================================================================
DOCUMENT 1: USCOURTS-cofc-1_24-vv-01697-0
Date issued/filed: 2025-08-11
Pages: 2
Docket text: PUBLIC ORDER/RULING (Originally filed: 07/11/2025) regarding 19 Ruling on Entitlement ( Signed by Chief Special Master Brian H. Corcoran. )(mpj) Service on parties made.
--------------------------------------------------------------------------------
Case 1:24-vv-01697-UNJ Document 22 Filed 08/11/25 Page 1 of 2
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 24-1697V
CHARLES JONES,
Chief Special Master Corcoran
Petitioner,
v. Filed: July 11, 2025
SECRETARY OF HEALTH AND
HUMAN SERVICES,
Respondent.
Leah VaSahnja Durant, Law Offices of Leah V. Durant, PLLC, Washington, DC, for
Petitioner.
Dima Jawad Atiya, U.S. Department of Justice, Washington, DC, for Respondent.
RULING ON ENTITLEMENT1
On October 18, 2024, Charles Jones filed a petition for compensation under the
National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.2 (the
“Vaccine Act”). Petitioner alleged that he suffered Guillain-Barré Syndrome (“GBS”), a
defined Table injury, after receiving an influenza (“flu”) vaccine on October 1, 2023.
Petition at 1 ¶¶ 1, 38. Petitioner also alleged that he continues to suffer the residual effects
of his GBS more than six months post-vaccination and that neither he nor any other party
has filed a civil action or received compensation for his GBS illness, alleged as vaccine-
1 Because this Ruling contains a reasoned explanation for the action taken in this case, it must be made
publicly accessible and will be posted on the United States Court of Federal Claims' website, and/or
at https://www.govinfo.gov/app/collection/uscourts/national/cofc, in accordance with the E-Government
Act of 2002. 44 U.S.C. § 3501 note (2018) (Federal Management and Promotion of Electronic Government
Services). This means the Ruling will be available to anyone with access to the internet. In accordance
with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information,
the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that
the identified material fits within this definition, I will redact such material from public access.
2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease
of citation, all section references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. §
300aa (2018).

Case 1:24-vv-01697-UNJ Document 22 Filed 08/11/25 Page 2 of 2
related. Id. at ¶¶ 38-39. The case was assigned to the Special Processing Unit of the
Office of Special Masters.
On July 11, 2025, Respondent filed his Rule 4(c) Report in which he concedes that
Petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report at 1.
Specifically, Respondent believes “that [P]etitioner has satisfied the criteria set forth in
the Vaccine Injury Table (“Table”) and the Qualifications and Aids to Interpretation (“QAI”),
which afford [P]etitioner a presumption of causation.” Id. at 4-5.
In view of Respondent’s position and the evidence of record, I find that
Petitioner is entitled to compensation.
IT IS SO ORDERED.
s/Brian H. Corcoran
Brian H. Corcoran
Chief Special Master
2

================================================================================
DOCUMENT 2: USCOURTS-cofc-1_24-vv-01697-1
Date issued/filed: 2026-04-10
Pages: 12
Docket text: PUBLIC DECISION (Originally filed: 03/10/2026) regarding 30 DECISION of Special Master. ( Signed by Chief Special Master Brian H. Corcoran. )(mpj) Service on parties made.
--------------------------------------------------------------------------------
Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 1 of 12
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 24-1697V
CHARLES JONES,
Chief Special Master Corcoran
Petitioner,
v. Filed: March 10, 2026
SECRETARY OF HEALTH AND
HUMAN SERVICES,
Respondent.
Leah VaSahnja Durant, Law Offices of Leah V. Durant, PLLC, Washington, DC, for
Petitioner.
Dima Jama Atiya, U.S. Department of Justice, Washington, DC, for Respondent.
DECISION AWARDING DAMAGES1
On October 18, 2024, Charles Jones filed a petition for compensation under the
National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.2 (the
“Vaccine Act”). Petitioner alleged that he suffered Guillain-Barré syndrome (“GBS”), a
defined Table injury, after receiving an influenza (“flu”) vaccine on October 1, 2023.
Petition at 1, ¶¶ 1, 38. The matter was assigned to the “Special Processing Unit” (the
“SPU”), and although Respondent conceded entitlement, the parties were unable to
resolve damages on their own,3 so I ordered briefing on the matter.
1 Because this Decision contains a reasoned explanation for the action taken in this case, it must be made
publicly accessible and will be posted on the United States Court of Federal Claims' website, and/or
at https://www.govinfo.gov/app/collection/uscourts/national/cofc, in accordance with the E-Government
Act of 2002. 44 U.S.C. § 3501 note (2018) (Federal Management and Promotion of Electronic Government
Services). This means the Decision will be available to anyone with access to the internet. In
accordance with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other
information, the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I
agree that the identified material fits within this definition, I will redact such material from public access.
2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease
of citation, all section references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. §
300aa (2018).
3 Approximately two months after Petitioner was determined entitled to compensation, he informed me that
the parties had reached an impasse in their damages discussions and requested “that the matter be slated
for further litigation.” Status Report at 2, ECF at 24.

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 2 of 12
For the reasons set forth below, I find that Petitioner is entitled to an award of
damages in the amount $178,000.00 for past pain and suffering.
I. Legal Standard
Compensation awarded pursuant to the Vaccine Act shall include “[f]or actual and
projected pain and suffering and emotional distress from the vaccine-related injury, an
award not to exceed $250,000.” Section 15(a)(4). Additionally, a petitioner may recover
“actual unreimbursable expenses incurred before the date of judgment award such
expenses which (i) resulted from the vaccine-related injury for which petitioner seeks
compensation, (ii) were incurred by or on behalf of the person who suffered such injury,
and (iii) were for diagnosis, medical or other remedial care, rehabilitation . . . determined
to be reasonably necessary.” Section 15(a)(1)(B). The petitioner bears the burden of proof
with respect to each element of compensation requested. Brewer v. Sec’y of Health &
Hum. Servs., No. 93-0092V, 1996 WL 147722, at *22-23 (Fed. Cl. Spec. Mstr. Mar. 18,
1996).
There is no mathematic formula for assigning a monetary value to a person’s pain
and suffering and emotional distress. I.D. v. Sec’y of Health & Hum. Servs., No. 04-1593V,
2013 WL 2448125, at *9 (Fed. Cl. Spec. Mstr. May 14, 2013) (“[a]wards for emotional
distress are inherently subjective and cannot be determined by using a mathematical
formula”); Stansfield v. Sec’y of Health & Hum. Servs., No. 93-0172V, 1996 WL 300594,
at *3 (Fed. Cl. Spec. Mstr. May 22, 1996) (“the assessment of pain and suffering is
inherently a subjective evaluation”). Factors to be considered when determining an award
for pain and suffering include: 1) awareness of the injury; 2) severity of the injury; and 3)
duration of the suffering. I.D., 2013 WL 2448125, at *9 (quoting McAllister v. Sec’y of
Health & Hum. Servs., No 91-1037V, 1993 WL 777030, at *3 (Fed. Cl. Spec. Mstr. Mar.
26, 1993), vacated and remanded on other grounds, 70 F.3d 1240 (Fed. Cir. 1995)).
I may also consider prior pain and suffering awards to aid my resolution of the
appropriate amount of compensation for pain and suffering in this case. See, e.g., Doe
34 v. Sec’y of Health & Hum. Servs., 87 Fed. Cl. 758, 768 (2009) (finding that “there is
nothing improper in the chief special master’s decision to refer to damages for pain and
suffering awarded in other cases as an aid in determining the proper amount of damages
in this case.”). And, of course, I may rely on my own experience (along with my
predecessor Chief Special Masters) adjudicating similar claims. Hodges v. Sec’y of
Health & Hum. Servs., 9 F.3d 958, 961 (Fed. Cir. 1993) (noting that Congress
contemplated the special masters would use their accumulated expertise in the field of
vaccine injuries to judge the merits of individual claims).
2

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 3 of 12
Although pain and suffering in the past was often determined based on a
continuum, as Respondent argues, that practice was cast into doubt by the Court several
years ago. Graves v. Sec’y of Health & Hum. Servs., 109 Fed. Cl. 579 (Fed. Cl. 2013).
Graves maintained that to do so resulted in “the forcing of all suffering awards into a global
comparative scale in which the individual petitioner’s suffering is compared to the most
extreme cases and reduced accordingly.” Id. at 590. Instead, Graves assessed pain and
suffering by looking to the record evidence, prior pain and suffering awards within the
Vaccine Program, and a survey of similar injury claims outside of the Vaccine Program.
Id. at 595. Under this alternative approach, the statutory cap merely cuts off higher pain
and suffering awards – it does not shrink the magnitude of all possible awards as falling
within a spectrum that ends at the cap. Although Graves is not controlling of the outcome
in this case, it provides reasoned guidance in calculating pain and suffering awards.
II. Prior SPU Compensation of GBS Pain and Suffering
A. General Data Regarding Compensation in SPU Flu/ GBS Cases
Flu/GBS cases have an extensive history of informal resolution within the SPU. As
of January 1, 2026, 1,004 GBS cases have been resolved since SPU’s inception ten
years ago. Compensation has been awarded in the vast majority of cases (954), with the
remaining 50 cases dismissed.
The data for all categories of theses damages decisions reflect the expected
differences in outcome, summarized as follows:
Damages Proffered Stipulated Stipulated4
Decisions by Damages Damages Agreement
Special Master
Total Cases 72 475 23 384
Lowest $96,008.66 $9,050.40 $20,000.00 $3,098.64
1st Quartile $148,568.21 $125,000.00 $142,500.00 $100,000.00
Median $167,100.02 $165,000.00 $252,000.00 $150,000.00
3rd Quartile $186,457.51 $240.831.00 $386,685.56 $216,030.00
Largest $244,390.18 $2,282,465.84 $985,000.00 $1,200,000.00
4 One award was for an annuity only, the exact amount which was not determined at the time of judgment.
3

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 4 of 12
B. Adjudication of Pain and Suffering in GBS Cases
Only a small minority of cases have involved a special master’s adjudication of
damages issues. The written decisions setting forth such determinations provide the most
reliable guidance in deciding what similarly-situated claimants should also receive.5
As of January 1, 2026, on nearly every occasion that SPU has had to resolve the
appropriate award for GBS-associated pain and suffering, over $100,000.00 has been
awarded (with a lower sum ($92,500.00) only awarded once). The remaining sixty-one
(71) awards far exceeded $100,000.00. The first-quartile value is $145,000.00. The
median is $161,500.00. The third-quartile value is $175,000.00. The largest award was
$225,000.00.
These decisions are informed by what is known about GBS, including its
description as set forth in the Vaccine Injury Table (“Table”). Pursuant to the Table,
vaccine causation is presumed for GBS with an onset 3 - 42 days (not less than 3 days,
and not more than 42 days) after receipt of a seasonal flu vaccine. 42 C.F.R. §
100.3(a)(XIV)(D). The Qualifications and Aids to Interpretation (“QAI”) explain:
GBS is an acute monophasic peripheral neuropathy that encompasses a
spectrum of four clinicopathological subtypes… The interval between the
first appearance of symptoms and the nadir of weakness is between 12
hours and 28 days. This is followed in all subtypes by a clinical plateau with
stabilization at the nadir of symptoms, or subsequent improvement without
significant relapse. Death may occur without a clinical plateau. Treatment-
related fluctuations in all subtypes of GBS can occur within 9 weeks of GBS
symptom onset, and recurrence of symptoms after this timeframe would not
be consistent with GBS.
42 C.F.R. § 100.3(c)(15)(I) (2017). The three most common subtypes are acute
inflammatory demyelinating polyneuropathy (“AIDP”); acute motor axonal neuropathy
(“AMAN”); and acute motor and sensory neuropathy (“AMSAN”). Id. The onset of each is
marked by “bilateral flaccid limb weakness and decreased or absent deep tendon reflexes
in weak limbs.” Id. at (c)(15)(II). The fourth subtype – Fisher syndrome or Miller-Fisher
5 Of course, even though all independently-settled damages issues (whether by stipulation/settlement or
proffer) must still be approved by a special master, such determinations do not provide the same judicial
guidance or insight obtained from a reasoned decision. But given the aggregate number of such cases,
these determinations nevertheless “provide some evidence of the kinds of awards received overall in
comparable cases.” Sakovits v. Sec’y of Health & Hum. Servs., No. 17-1028V, 2020 WL 3729420, at *4
(Fed. Cl. Spec. Mstr. June 4, 2020) (discussing the difference between cases in which damages are agreed
upon by the parties and cases in which damages are determined by a special master).
4

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 5 of 12
syndrome – has a different onset of “bilateral ophthalmoparesis; bilateral reduced or
absent tendon reflexes; [and] ataxia.” Id. at (c)(15)(III).6
A consistent starting consideration in determining pain and suffering awards in the
context of a GBS injury is that the amounts should exceed “those awarded to petitioners
who have suffered a less frightening and physically alarming injury, such as SIRVA.”7
Gross v. Sec’y of Health & Hum. Servs., No. 19-0835V, 2021 WL 2666685, at *5 (Fed.
Cl. Spec. Mstr. March 11, 2021); see also, e.g., Castellanos v. Sec’y of Health & Hum.
Servs., No. 19-1710V, 2022 WL 1482497, at *10 (Fed. Cl. Spec. Mstr. Mar. 30, 2022)
(emphasizing recognition of “the seriousness of GBS as a general matter,” in awarding a
six-figure sum); Voeller v. Sec’y of Health & Hum. Servs., No. 20-1526V, 2023 WL
5019830, at *10 (Fed. Cl. Spec. Mstr. July 6, 2023) (noting GBS’s “frightening” nature).
But of course, not every GBS case is equally severe. Further details of the initial
medical course are considered – including any mistake or delay in diagnosing GBS; any
in-patient hospitalization and/or in-patient rehabilitation (and the duration of any such
stays); diagnostic procedures (e.g., bloodwork, lumbar punctures, electrodiagnostic
studies, imaging); the severity of symptoms at their nadir (e.g., involving incontinence or
respiratory failure); the extent and effectiveness of treatment (e.g., IVIg, plasmapheresis,
pain medications); other interventions (e.g., feeding tubes, breathing tubes,
catheterization); and any complications (e.g., sepsis during hospitalization).
Also relevant is a petitioner’s long-term course – as evidenced by out-patient
therapies, neurology evaluations, and other medical appointments concerning GBS; the
results of repeat electrodiagnostic studies and other relevant tests; medical providers’
assessments of the degree of recovery achieved; ongoing reliance on assistive devices
and medications; and relevant treatment gaps. Previous opinions have recognized that
“a substantial recovery does not mean that [an individual] has fully recovered from his
GBS and has no ongoing sequelae. It is common for petitioners to experience ongoing
symptoms of GBS, such as numbness and fatigue, even with a good recovery.” Elenteny
v. Sec’y of Health & Hum. Servs., No. 19-1972V, 2023 WL 2447498, at *5 (Fed. Cl. Spec.
Mstr. Mar. 10, 2023). But symptoms of that nature are typically folded into a “typical” past
pain and suffering award, and will not justify a future component. See, e.g., id.; Miller v.
6 See also National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table – Notice
of Proposed Rulemaking, 80 Fed. Reg. 45132, at 45144 – 45 (July 29, 2015) (proposing addition of Table
flu/GBS claims – explaining GBS is “an acute paralysis caused by dysfunction in the peripheral nervous
system [that…] may manifest with weakness, abnormal sensations, and/or abnormality in the autonomic
(involuntary) nervous system,” and that death, when it occurs, is most often related to respiratory failure).
7 Shoulder injury related to vaccine administration (“SIRVA”) is another Table injury. 42 C.F.R. §§ 100.3(a),
(c)(10).
5

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 6 of 12
Sec’y of Health & Hum. Servs., No. 21-1559V, 2023 WL 2474322, at *8 (Fed. Cl. Spec.
Mstr. Feb. 10, 2023).
In addition, “[t]he mere fact that a claimant had pre-vaccination comorbidities does
not per se diminish the impact of [the vaccine injury] on his life – especially one as
alarming and potentially life-altering as GBS – and therefore is not alone reason for a
lower award.” Bircheat v. Sec’y of Health & Hum. Servs., No. 19-1088V, 2021 WL
3026880, at *4 (Fed. Cl. Spec. Mstr. June 16, 2021). But a special master is statutorily
required to consider to what extent a petitioner’s pain and suffering is truly “from the
vaccine-related injury,” Section 15(a)(4) (emphasis added), and not from any unrelated
preexisting or subsequently-developed medical issues. See, e.g., Bircheat, 2021 WL
3026880, at *4; Gross, 2021 WL 2666685, at *5.
Also worthy of consideration are the injury’s impact on a petitioner’s personal
circumstances including his or her family and other personal obligations, and professional
life (whether or not lost wages are directly claimed).
All of these facts are primarily gleaned from the medical records – although sworn
statements and/or other evidence often supplements the record evidence, and/or
corroborates important fact contentions.
III. The Parties’ Arguments
Seeking compensation for past pain and suffering in the amount of $185,000.00.,
Petitioner characterizes his illness as severe and debilitating. Petitioner’s Brief on
Damages (“Brief”), filed Nov. 17, 2025, at 17, ECF No. 27. He insists that “[t]he medical
records in this case paint a clear picture of [his] rapid and severe GBS onset, followed by
an extensive course of treatment that has not fully restored [his] health.” Id. He
emphasizes his 17-day hospitalization - began eleven days post-vaccination and
interrupted once by an unsuccessful two-day attempt at rehabilitation; 25 days of inpatient
rehabilitation thereafter; continued need for a walker or cane even after returning home;
at least 105 physical therapy (“PT”) sessions during the subsequent year and three
months; and continued symptoms such as a pins and needles feeling in his feet, balance
issues, sleep loss, fatigue, back pain, lack of energy, and gastrointestinal issues. Id. at
17-19. To support his assertion of residual symptoms, Petitioner provided updated
medical records from treatment received July 2024 through February 2025. Exs. 15-18,
ECF No. 26.
Petitioner favorably compares the facts and circumstances in his case to those
6

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 7 of 12
experienced by the petitioners in McCray, Johnson, and Fedewa8 – decisions involving
past pain and suffering awards of $180,000.00. Brief at 20-22. Noting shared similarities
with the McCray petitioner – specifically the duration of the hospital stays and inpatient
rehabilitation - Petitioner argues that his award should be slightly greater because he
required 30 PT sessions during the two, post-hospitalization months when he could
ambulate unassisted. Id. at 20. Regarding Johnson and Fedewa, Petitioner emphasizes
the longer duration of his hospital and inpatient rehabilitation and more extensive
treatment. Id. at 21. And he equates his receipt of a clear diagnosis only after seeking
treatment three times with the difficulties the Fedewa petitioner experienced obtaining his
GBS diagnosis.
Characterizing Petitioner’s GBS illness as moderate, Respondent counters that
$148,000.00 is an appropriate amount for Petitioner’s past pain and suffering.
Respondent’s Brief on Damages (“Opp.”), filed Nov. 17, 2025, at 1, 5. To support his
assertion that “[t]he overall sequela of [P]etitioner’s GBS was nine months,” Respondent
cites Petitioner’s report that he was able to do some cross country skiing four months
post-vaccination in February 2024, was hiking and had stopped taking Gabapentin six
months post-vaccination in April 2024, and was doing well at his last neurology
appointment seven months post-vaccination in May 2024.
As comparable cases, Respondent proposes Castellanos and Schenck9 -involving
past pain and suffering awards of $125,000.00 and $150,000.00, respectively. Opp. at 6-
7. Respondent contends, however, that Petitioner’s award should be slightly less than
$150,000.00 because the Schenck petitioner experienced personal difficulties (not
present in Petitioner’s case) such as an inability to care for his wife following her brain
surgery. Id. at 7. Respondent insists that “[o]verall, [P]etitioner’s course was less severe
than those in previous cases where damages were decided by the Court” such as
Dillenbeck, Johnson, and Fedewa.10 Opp. at 7-8.
One month after the parties’ initial briefs, Respondent filed a reply, acknowledging
that the updated medical records provided by Petitioner “support a finding that this case
8 McCray v. Sec'y of Health & Hum. Servs., No. 19-0277V, 2021 WL 4618549 (Fed. Cl. Spec. Mstr. Aug.
31, 2021); Johnson v. Sec'y of Health & Hum. Servs., No. 16-1356V, 2018 WL 5024012 (Fed. Cl. Spec.
Mstr. July 20, 2018); Fedewa v. Sec'y of Health & Hum. Servs., No. 17-1808V, 2020 WL 1915138 (Fed. Cl.
Spec. Mstr. Mar. 26, 2020).
9 Castellanos v. Sec’y of Health & Hum. Servs., No. 19-1710V, 2022 WL 1482497 (Fed. Cl. Spec. Mstr.
Mar. 30, 2022); Schenck v. Sec’y of Health & Hum. Servs., No. 21-1768V, 2023 WL 2534594 (Fed. Cl.
Spec. Mstr. Mar. 16, 2023).
10 Dillenbeck v. Sec'y of Health & Hum. Servs., No. 17-0428V, 2019 WL 4072069 (Fed. Cl. Spec. Mstr.
July 29, 2019), aff’d in relevant part 147 Fed. Cl. 131 (2020) (awarding $170,000.00 for past pain and
suffering) Johnson, 2018 WL 5024012; Fedewa, 2020 WL 1915138.
7

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 8 of 12
warrants a slightly higher award than the $148,000 previously advanced for in
[R]espondent’s brief on damages.” Respondent’s Responsive Brief on Damages at 1,
ECF No. 28. Noting several relevant entries (id. at 2-3), Respondent “acknowledges that
. . . [P]etitioner experienced a moderately severe course of GBS . . . for at least two years”
(id. at 5). He still insists, however, that the appropriate pain and suffering award should
be lower than the $185,000.00 Petitioner seeks. Id. at 7.
In his reply filed one week later, Petitioner insists that the comparable cases
proposed by Respondent are not analogous because those petitioners suffered milder
GBS illnesses. Petitioner’s Reply to Opp. at 2-4. He contends that the significant
difference in the amount awarded in Castellanos and that proposed by Respondent
shows “Castellanos is particularly inapposite.” Id. at 2. He again argues that his
hospitalization, rehabilitation, and treatment were more extensive than for the Johnson
and Fedewa petitioners, as well as the petitioner in the Dillenbeck case cited by
Respondent. Id. at 4-6.
IV. Appropriate Compensation for Pain and Suffering
In this case, awareness of the injury is not disputed. The record reflects that at all
times Petitioner was a competent adult with no impairments that would impact her
awareness of her injury. Therefore, I analyze principally the severity and duration of
Petitioner’s injury.
In performing this analysis, I have reviewed the record as a whole, including the
medical treatment evidence, affidavits, and all assertions made by the parties in written
documents. I considered prior awards for pain and suffering in both SPU and non-SPU
GBS cases and rely upon my experience adjudicating these cases. However, I ultimately
base my determination on the circumstances of this case.
The evidence shows that Petitioner - age 76 and physically active when vaccinated
- suffered a moderate case of GBS, involving common symptoms such as weakness, leg
pain, tingling and numbness in the upper and lower extremities as well as a cold feeling
in his hands, and gait and balance issues. During hospitalizations and inpatient
rehabilitation lasting more than one month, Petitioner obtained slow improvement but also
suffered a slight worsening of symptoms – developing abdomen pain and bowel issues,
some increased difficulty ambulating, and minor problems breathing. Although he
required significant PT after returning home (more than 100 sessions at home and in
clinic), he was able to bike ride and hike less than a year after symptom onset. But the
record reflects well-documented residual effects of Petitioner’s GBS illness for at least
two years.
8

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 9 of 12
Petitioner first sought treatment on October 11, 2023, from his primary care
provider (“PCP”), and then at a later emergency room (“ER”) visit, complaining of
weakness and fatigue, coldness in his hands, and tingling in the hands and feet. Ex. 5 at
19-20 (PCP visit); Ex. 2 at 35-39 (ER visit). His symptoms advanced quickly, and he was
forced to use a walker by his return to the ER the next day (on October 12th). Ex. 2 at 40.
However, Petitioner was immediately diagnosed with GBS (which testing confirmed) and
admitted to the hospital. Id. at 40-59. Although he, no doubt, had grave concerns during
this time, his failure to obtain a proper diagnosis on October 11th, does not rise to the level
of the difficulties experienced by the Fedewa petitioner – including a fall and inability to
get up in his front yard between ER visits and significant complications when undergoing
a second lumbar puncture and EMG testing. See Fedewa, 2020 WL 1915138, at 3.
Despite his rapid diagnosis before his symptoms became severe, Petitioner also
developed abdominal pain and bowel issues, and obtained only slow improvement with
treatment while hospitalized.11 After seven days, he was transferred to an inpatient
rehabilitation facility but was forced to return to a different hospital two days later due to
increased leg pain and a concern regarding his breathing.12 Reporting that he felt weaker
than previously, Petitioner spent an additional ten days in this hospital (without requiring
respiratory support) and 25 days thereafter in another inpatient rehabilitation.13
11 Petitioner began a five-day course of IVIG treatment on October 12, 2023. Ex. 2 at 56. Although he
presented with significant weakness, on October 13, 2023, it was noted that he was able to dress and go
to the bathroom independently. Id. at 60. After Petitioner developed “some abdominal pain” (id. at 69)
following his third day of IVIG therapy, his family expressed a desire for tertiary care but were reassured he
was receiving all available treatment. Id. at 69-70. It was noted that “the patient does not have any shortness
of breath . . . and his weakness remains stable and slowly improving. He predominately complains of his
abdominal pain we will do further work-up but may also be due to his constipation.” Id. at 70. Despite taking
Gabapentin, Petitioner’s pain was noted to be poorly controlled, and he reported new abdominal pain on
October 14, 2023. Id. at 78-79. On October 15, 2023, it was noted that Petitioner “ha[d] been slowly
improving though easily [got] fatigued and tired with pain in his lower extremities with numbness or
paresthesias.” Id. at 84. After his fifth and final day of IVIG therapy, Petitioner continued to experience
weakness and was started on IV steroids. Id. at 104. By October 17th, Petitioner’s abdominal pain and
constipation was noted to be improving. Id. at 120.
12 Petitioner was switched to oral steroids based on his family’s preference and transferred to an inpatient
rehabilitation on October 20, 2023. Ex. 12 at 19; Ex. 3 at 91. That evening he had difficulty sleeping due to
an increase in his neuropathic leg pain. Id. He was transferred to a different hospital on October 21, 2023,
after reporting “a ‘constricting band’ around his abdomen” and more labored breathing, especially with slight
movements. Ex. 3 at 91; accord. Ex. 12 at 19.
13 Petitioner’s breathing was monitored during this second hospital stay, but it was determined that he did
not require respiratory support. Ex. 3 at 95. He was able to feed himself but required a wheelchair and sling
to transfer from the bed. Id. at 99. Upon his discharge from inpatient therapy, Petitioner was noted to require
several months of PT but had inside mobility. Ex. 4 at 45. He was provided a sliding board to aid in transfers
and shown how to operate his wheelchair when outdoors. Id. at 45-56.
9

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 10 of 12
After his discharge on November 25, 2023, Petitioner continued to experience
abdominal issues, weakness, and fatigue, but made good (albeit slow) progress during
PT through July 2024.14 A physically active retired physics teacher prior to his GBS
illness, Petitioner reported some success cycling and hiking in August 2024.15 However,
he continued to require PT - attending an additional 40 sessions in clinic through
December 2024. Ex. 16. By September 2024, Petitioner stated that “he went for a walk
yesterday and it was the first time he felt like he was walking faster and almost normal.”
Ex. 16 at 171. At a neurology appointment in October 2025, Petitioner recounted “[n]ot
having any pain per se [b]ut . . . continued pins and needles in the feet.” Ex. 17 at 2. He
also stated that he had finished PT, was continuing to perform exercises to help with
balance and was going to PT for back pain. Id.
In addition to Fedewa, I do not find the Schenck or Castellanos cases helpful when
determining the appropriate pain and suffering award in this case. The Schenck
petitioner’s award was based in large part upon specific personal circumstances not found
here. Schenck, 2023 WL 2534594, at *3. And I was required to issue a ruling in
Castellanos finding six-months sequela in which I also determined that the later
symptoms alleged as vaccine-related were more likely due to unrelated co-morbidities.
Castellanos, 2022 WL 1482497, at *7, 10. Thus, the Castellanos petitioner’s GBS illness
was clearly less severe. Id. at *9-10.
In contrast, the McCray, Johnson, and Dillenbeck cases offer some helpful
guidance. However, the age of the Johnson determination – issued in 2018,16 dilutes its
probative value. And the Dillenbeck petitioner’s inability to return to a job that she loved
was a factor when determining her award. Dillenbeck, 2019 WL 4072069, at *14. Although
Petitioner’s enjoyment of activities such as biking and hiking could be similarly viewed,
the record shows he was able to participate in these activities post-illness.
14 A few days after his discharge, Petitioner visited his PCP for treatment of constipation, reporting improved
motor function during rehabilitation, a continued need for Gabapentin to address his neuropathy pain, and
receiving PT through home health. Ex. 5 at 24. He participated in 37 PT sessions through January 2024,
and an additional 15 PT sessions from May through July 2024. Exs. 7, 9 (PT records). By early January
2024, he could navigate stairs but continued to exhibit fatigue and balance issues. Ex. 7 at 105. By late
July 2024, Petitioner reported improvement in neuropathy pain as well, stating “sometimes it’s background
noise but other days it can still be very intense.” Ex. 9 at 31.
15 In an email communication with his neurologist on August 30, 2024, Petitioner reported that he “had been
doing well in recovering, now doing some trail hiking, cycling (up to 60 mi[les] on occasion), seeing a great
PT twice weekly emphasizing ankle and toe strength and balance, doing a 20 min[ute] core exercise routine,
and strength training at a PT fitness center.” Ex. 15 at 37. He added that “[a]s of 3 weeks ago [his]
neuropathy had receded to [his] toes and [his] walking was becoming more natural.” Id.
16 Issued by former Chief Special Master Dorsey in August 2018, the Johnson decision was the first
substantive damages decision issued in an SPU Flu/GBS case. Johnson, 2018 WL 5024012.
10

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 11 of 12
Besides McCray, I also find the J.S., Ruppert, and Elenteny17 cases (reflecting past
pain and suffering awards ranging from $178,000.00 to $180,000.00) to be particularly
instructive. All involved moderate GBS symptoms, lengthy hospital and inpatient
rehabilitation stays, and significant outpatient PT thereafter. The Elenteny petitioner had
a longer duration of documented residual symptoms (2.75 years) and never returned to
her baseline. Elenteny, 2023 WL 2447498, at *2. And the Ruppert petitioner was forced
to contend with a significant co-morbidity (cancer) during her illness. Ruppert, 2023 WL
9063679, at *8. Although he only sought treatment for ten months, the J.S. petitioner had
well-documented residual sequela. J.S., 2024 WL 3326833, at *3, 7. Also an active
retiree, he experienced symptoms that most closely mirrored Petitioner’s and required 33
days of inpatient rehabilitation followed by almost 100 outpatient therapy sessions. Id. at
*1-3, 6-7. Thus, the J.S. case offers the best comparison, and Petitioner should be
awarded the same amount of compensation for his past pain and suffering.
Conclusion
For all of the reasons discussed above and based on consideration of the record
as a whole, I find that $178,000.00 represents a fair and appropriate amount of
compensation for Petitioner’s past/actual pain and suffering.18
I therefore award Petitioner a lump sum payment of $178,000.00,
representing compensation for his actual pain and suffering, to be paid through an
ACH deposit to Petitioner’s counsel’s IOLTA account for prompt disbursement to
Petitioner. This amount represents compensation for all damages that would be available
under Section 15(a).
The Clerk of the Court is directed to enter judgment in accordance with this
Decision.19
17 J.S. v. Sec'y of Health & Hum. Servs., No. 22-0879V, 2024 WL 3326833 (Fed. Cl. Spec. Mstr. Apr. 29,
2024) (awarding $178,000.00 for past pain and suffering); Ruppert v. Sec'y of Health & Hum. Servs., No.
18-1621V, 2023 WL 9063679 (Fed. Cl. Spec. Mstr. Nov. 30, 2023) (awarding $180,000.00 for past pain
and suffering); Elenteny v. Sec'y of Health & Hum. Servs., No. 19-1972V, 2023 WL 2447498 (Fed. Cl. Spec.
Mstr. Feb. 1, 2023) (awarding $180,000.00 for past pain and suffering)
18 Since this amount is being awarded for actual, rather than projected, pain and suffering, no reduction to
net present value is required. See Section 15(f)(4)(A); Childers v. Sec’y of Health & Hum. Servs., No. 96-
0194V, 1999 WL 159844, at *1 (Fed. Cl. Spec. Mstr. Mar. 5, 1999) (citing Youngblood v. Sec’y of Health &
Hum. Servs., 32 F.3d 552 (Fed. Cir. 1994)).
19 Pursuant to Vaccine Rule 11(a), entry of judgment can be expedited by the parties’ joint filing of notice
renouncing the right to seek review.
11

Case 1:24-vv-01697-UNJ Document 31 Filed 04/10/26 Page 12 of 12
IT IS SO ORDERED.
s/Brian H. Corcoran
Brian H. Corcoran
Chief Special Master
12